for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Emergent Biosolutions Inc

EBS

Latest Trade

42.32USD

Change

0.43(+1.03%)

Volume

471,313

Today's Range

41.46

 - 

42.89

52 Week Range

29.88

 - 

127.20

As of on the New York Stock Exchange ∙ Minimum 15 minute delay

Latest Developments

Health Canada Announces Results Of Emergent Biosolutions Facility Inspection

Nov 24 (Reuters) - Health Canada: :HEALTH CANADA ANNOUNCES RESULTS OF EMERGENT BIOSOLUTIONS FACILITY INSPECTION.HEALTH CANADA - ALL THREE REGULATORS FOUND FACILITY TO BE COMPLIANT WITH GOOD MANUFACTURING PRACTICES.HEALTH CANADA - EUROPEAN MEDICINES AGENCY AND SOUTH AFRICAN HEALTH PRODUCTS REGULATORY AUTHORITY ALSO PARTICIPATED IN THIS INSPECTION REMOTELY.HEALTH CANADA - COMPLIANT RATING MEANS JANSSEN TO BE ABLE TO IMPORT THEIR VACCINES INTO CANADA MADE WITH DRUG SUBSTANCE MANUFACTURED AT EMERGENT'S FACILITY.

Emergent BioSolutions Reports Financial Results For Q3 2021

Nov 4 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR THIRD QUARTER 2021.QTRLY ADJUSTED LOSS PER SHARE $0.36.QTRLY LOSS PER SHARE $0.61.QTRLY TOTAL REVENUE $329 MILLION VERSUS $385.2 MILLION.SEES 2021 TOTAL REVENUE $1,700 MILLION TO $1,800 MILLION.SEES 2021 TOTAL ADJUSTED NET INCOME OF $315 MILLION TO $350 MILLION.FY2021 REVENUE VIEW $1.80 BILLION -- REFINITIV IBES DATA.

Emergent Says Working With AstraZeneca On Documentation For US Govt COVID-19 Vaccine Dose Shipments: Conf Call

July 29 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT SAYS WORKING WITH ASTRAZENECA ON DOCUMENTATION FOR US GOVERNMENT COVID-19 VACCINE DOSE SHIPMENTS: CONF CALL.EMERGENT SAYS EXPECTS TO BEGIN LATE STAGE STUDY IN PARTNERSHIP WITH US GOVERNMENT OF COVID-19 THERAPY CANDIDATE IN NEAR TERM: CONF CALL.EMERGENT EXECUTIVE SAYS EXPECTS FDA TO APPROVE THE USE OF ADDITIONAL J&J BATCHES ALREADY MANUFACTURED: CONF CALL.

Emergent Biosolutions Reports Financial Results For Second Quarter 2021

July 29 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS REPORTS FINANCIAL RESULTS FOR SECOND QUARTER 2021.SEES Q3 REVENUE $400 MILLION TO $500 MILLION.Q2 REVENUE $190.9 MILLION.Q2 REVENUE ESTIMATE $398.9 MILLION -- REFINITIV IBES DATA.REAFFIRMS 2021 FULL YEAR FORECAST FOR REVENUES AND PROFIT.Q3 REVENUE VIEW $495.4 MILLION -- REFINITIV IBES DATA.FY2021 REVENUE VIEW $1.80 BILLION -- REFINITIV IBES DATA.EMERGENT BIOSOLUTIONS - QTRLY EARNINGS PER SHARE $0.09 ; QTRLY ADJUSTED EARNINGS PER SHARE $0.33.EMERGENT BIOSOLUTIONS - IN QUARTER, HAD INVENTORY WRITE-OFFS OF $41.5 MILLION.EMERGENT BIOSOLUTIONS - IN QUARTER, INVENTORY WRITE-OFFS RELATED TO RAW MATERIALS, IN-PROCESS BATCHES MANUFACTURED AT BAYVIEW FACILITY.EMERGENT BIOSOLUTIONS - FY OTHER PRODUCT SALES, EXPECTED TO BE IMPACTED ON ASSUMPTION THAT A NEW RAXIBACUMAB CONTRACT TO BE AWARDED LATER THAN PLANNED.

Emergent BioSolutions - Second Option Exercise Was Made Under Emergent's Existing 10-Year Contract Awarded By ASPR On August 30, 2019

July 14 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS - SECOND OPTION EXERCISE WAS MADE UNDER EMERGENT'S EXISTING 10-YEAR CONTRACT AWARDED BY ASPR ON AUGUST 30, 2019.EMERGENT BIOSOLUTIONS - ENTIRE AMOUNT IS EXPECTED TO BE DELIVERED IN FISCAL YEAR 2021.EMERGENT BIOSOLUTIONS INC - SECOND OPTION EXERCISE IS VALUED AT APPROXIMATELY $182.2 MILLION.EMERGENT BIOSOLUTIONS - PERIOD OF PERFORMANCE UNDER SECOND OPTION EXERCISE REQUIRES EMERGENT TO DELIVER DOSES OF ACAM2000 INTO SNS BY DECEMBER 31.EMERGENT BIOSOLUTIONS - ON JULY 13, CO THROUGH ITS UNIT EMERGENT PRODUCT DEVELOPMENT GAITHERSBURG RECEIVED A CONTRACT MODIFICATION FROM OFFICE OF ASPR.Further company coverage: EBS.N. ((Reuters.Briefs@thomsonreuters.com;)).

FDA Approves Additional Batch Of J&J's U.S.-Made Covid-19 Vaccine For Use

July 13 (Reuters) - U.S. FDA: :FDA APPROVES ADDITIONAL BATCH OF J&J'S U.S.-MADE COVID-19 VACCINE FOR USE.

FDA Poised To Clear Another Batch Of J&J Vaccine Made From Emergent Manufacturing Plant In Baltimore Today - Bloomberg

July 2 (Reuters) - :FDA POISED TO CLEAR ANOTHER BATCH OF J&J VACCINE MADE FROM EMERGENT MANUFACTURING PLANT IN BALTIMORE TODAY - BLOOMBERG REPORTER TWEET.

FDA Says Authorized Use For Janssen Covid-19 Vaccine Of Additional Batch Of Vaccine Drug Substance Manufactured At Emergent Facility

June 15 (Reuters) - :FDA SAYS AUTHORIZED USE, UNDER EUA FOR JANSSEN COVID-19 VACCINE, OF ADDITIONAL BATCH OF VACCINE DRUG SUBSTANCE MANUFACTURED AT EMERGENT FACILITY.FDA SAYS NOT YET READY TO INCLUDE THE EMERGENT BIOSOLUTIONS PLANT IN JANSSEN EUA AS AN AUTHORIZED MANUFACTURING FACILITY. ((reuters.briefs@thomsonreuters.com;)).

FDA Takes Steps To Increase Availability Of Covid-19 Vaccine

June 11 (Reuters) - U.S. FDA::FDA TAKES STEPS TO INCREASE AVAILABILITY OF COVID-19 VACCINE.FDA SAYS AUTHORIZING FOR USE, UNDER EUA FOR JANSSEN COVID-19 VACCINE 2 BATCHES OF VACCINE DRUG SUBSTANCE MANUFACTURED AT EMERGENT BIOSOLUTIONS FACILITY IN BALTIMORE.FDA SAYS IS TAKING STEPS THAT WILL ALLOW SUPPLY OF THE JANSSEN COVID-19 VACCINE TO BE MADE AVAILABLE.FDA SAYS IT HAS REVISED THE LETTER OF AUTHORIZATION FOR THE JANSSEN VACCINE TO HELP FACILITATE POTENTIAL EXPORT TO OTHER COUNTRIES.FDA SAYS FDA IS NOT YET READY TO INCLUDE EMERGENT BIOSOLUTIONS PLANT IN THE JANSSEN EUA AS AN AUTHORIZED MANUFACTURING FACILITY.FDA SAYS FDA CONTINUES TO WORK THROUGH ISSUES AT EMERGENT BIOSOLUTIONS PLANT WITH JANSSEN AND EMERGENT BIOSOLUTIONS MANAGEMENT.FDA SAYS UNDER REVISED LETTER OF AUTHORIZATION, DISTRIBUTION & ADMINISTRATION OF EXPORTED VACCINES MUST COMPLY WITH LAWS OF THE RECIPIENT COUNTRIES.FDA SAYS FDA HAS DETERMINED SEVERAL OTHER BATCHES ARE NOT SUITABLE FOR USE, BUT ADDITIONAL BATCHES ARE STILL UNDER REVIEW. ((Reuters.Briefs@thomsonreuters.com;)).

Emergent Biosolutions Announces Positive Two-Year Persistence Data From Phase 2 Study Evaluating Chikv Vlp

May 26 (Reuters) - Emergent BioSolutions Inc <EBS.N>::EMERGENT BIOSOLUTIONS ANNOUNCES POSITIVE TWO-YEAR PERSISTENCE DATA FROM PHASE 2 STUDY EVALUATING CHIKV VLP, THE COMPANY’S CHIKUNGUNYA VIRUS VIRUS-LIKE PARTICLE VACCINE CANDIDATE.EMERGENT - DOSE-RELATED INCREASE IN IMMUNE RESPONSE, AS MEASURED BY ANTI-CHIKUNGUNYA VIRUS SERUM NEUTRALIZING ANTIBODIES, WAS PREVIOUSLY OBSERVED.EMERGENT BIOSOLUTIONS - CHIKUNGUNYA VIRUS VIRUS-LIKE PARTICLE VACCINE CANDIDATE WAS WELL-TOLERATED.EMERGENT - MAJORITY OF SOLICITED ADVERSE EVENTS WERE MILD OR MODERATE IN SEVERITY & MOST FREQUENT WAS LOCAL INJECTION SITE PAIN.

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up